DDInter1853 DDInter484
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Tretinoin {u} (Compound) upregulates {v} (Gene) LYN
LYN {u} (Gene) is bound by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) downregulates {v} (Gene) SPDEF
SPDEF {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) upregulates {v} (Gene) LBR
LBR {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) binds {v} (Gene) GPRC5A
GPRC5A {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Tretinoin {u} (Compound) upregulates {v} (Gene) LYN
LYN {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Tretinoin (Compound) upregulates LYN (Gene) and LYN (Gene) is bound by Dasatinib (Compound)
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Tretinoin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Dasatinib (Compound)
Tretinoin (Compound) downregulates SPDEF (Gene) and SPDEF (Gene) is upregulated by Dasatinib (Compound)
Tretinoin (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Dasatinib (Compound)
Tretinoin (Compound) upregulates LBR (Gene) and LBR (Gene) is downregulated by Dasatinib (Compound)
Tretinoin (Compound) binds GPRC5A (Gene) and GPRC5A (Gene) is downregulated by Dasatinib (Compound)
Tretinoin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Tretinoin (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is bound by Dasatinib (Compound) and EPHA3 (Gene) is upregulated by Dasatinib (Compound)
Tretinoin (Compound) upregulates LYN (Gene) and LYN (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound)